摘要
我们采用治疗性乙肝疫苗（免疫复合物型和佐剂型）分别对１４５例各型乙型肝炎进行治疗，结果显示：乙肝主要指标ＡＬＴ复常率、ＨＢＶ－ＤＮＡ及ＨＢｅＡｇ阴转率，免疫复合物组分别为９２．９％、５０％和４１．９％；佐剂组分别为９４．１％、４２．８％和３５．２％，均明显高于对照组（Ｐ＜０．０１）。Ｔ细胞亚群中ＣＤ＋４／ＣＤ＋８细胞平均比值明显提高。试验表明：免疫复合物型疫苗和佐剂型疫苗对慢性肝炎，尤其是慢性活动性肝炎有较好疗效，而免疫复合物型优于佐剂型。本制剂无毒副作用。
145 cases of the hepatitis B were treated with Therapeutic Hepatitis B Vaccine (THBV,type immune complexes and type adjuvant).The results showed that the recovery rate of ALT and the negative conversion rate of HBV-M were 92.9%,50% and 41.9% in type immune complexes and they were 94.1%,42.8% and 35.2% in type adjuvant.They were higher significantly than those in normal controls (P<0.01).The ratios of CD+4/CD+8 rose obviously.The results indicated that THBV is efficacious for various hepatitis,especially for CAH.The curative effect of the type immune complexes is better than the type adjuvant.
出处
《微生物学免疫学进展》
1998年第3期50-53,共4页
Progress In Microbiology and Immunology
关键词
治疗性乙肝疫苗
免疫复合物
佐剂
乙型肝炎
Therapeutic Hepatitis B Vaccine Immune Compleses Adjuvant Hepatitis B
